Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC

EP: 1.Value of Comprehensive Molecular Testing in NSCLC

EP: 2.Unmet Needs in HER2-Mutant NSCLC

EP: 3.Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation

EP: 4.Overview of HER2-Targeted Therapies in NSCLC

EP: 5.Mechanistic Role of Emerging Tyrosine Kinase Inhibitors (TKIs) in HER2-Mutant NSCLC

EP: 6.Efficacy and Safety of Zongertinib in Previously Treated and Treatment-Naïve HER2-Mutant NSCLC from Beamion LUNG-1 Trial

EP: 7.Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial

Now Viewing

EP: 8.Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC

This episode examines the safety considerations and patient-reported outcomes associated with tyrosine kinase inhibitors (TKIs) in HER2-mutant non-small cell lung cancer (NSCLC). The discussion addresses common adverse effects of TKIs, such as diarrhea, rash, and nail changes, with sevabertinib demonstrating higher rates of rash and gastrointestinal toxicity compared to zongertinib. The panel contrasts these toxicity profiles with those of antibody-drug conjugates (ADCs), emphasizing that ADCs more frequently cause chemotherapy-like side effects, including cytopenias, nausea, fatigue, and notably, interstitial lung disease (ILD)—the latter being less commonly reported with TKIs. The impact of underlying conditions, such as pre-existing lung disease or immunotherapy-related toxicities, is highlighted as a key factor in therapy selection. The importance of patient-reported outcomes, including symptom improvement and quality of life, is underscored, reinforcing that both clinical safety data and individual patient experiences must guide optimal treatment choices for HER2-mutant NSCLC.